March 21st 2023
A retrospective cohort demonstrated that patients who are treated with antibiotics within 1 year before immune checkpoint inhibitor therapy may experience worse overall survival.
February 28th 2023
Adding Pembrolizumab to Lenvatinib Yields Similar HRQOL Scores As Lenvatinib Alone in HCC
January 20th 2023Patients with advanced hepatocellular carcinoma experienced similar health-related quality of life scores whether they received a combination of pembrolizumab and lenvatinib or lenvatinib and placebo.
Nivolumab/Ipilimumab May Be Most Effective mRCC Treatment, Sunitinib Most Cost-Effective
January 18th 2023A decision model with a 10-year time horizon found that nivolumab plus ipilimumab was the most effective combination for patients with metastatic renal cell carcinoma, but sunitinib was the most cost-effective approach.
Neoadjuvant Chemotherapy Makes Organ-Sparing Surgery More Accessible for Patients With Rectal Cancer
October 11th 2022Neoadjuvant chemotherapy allowed 79% of patients with early-stage I/IIA rectal cancer to pursue organ-sparing excision surgery, potentially preserving their quality of life and bowel function.
Nurse-Led Research Links Saturate Fatty Acids to Improved Immunotherapy Responses in NSCLC
September 23rd 2022Julie Malo, CCRP, a research nurse with the University of Montreal, discusses a nurse-directed initiative examining how the gut microbiome affects immune checkpoint blockade responses in patients with non–small cell lung cancer.
Real-World HRQOL Findings Support Nivolumab for Previously Treated mRCC
September 19th 2022Results of retrospective analysis of previously treated patients with metastatic renal cell carcinoma who received nivolumab in the second- and third-line showed that health-related quality of life was maintained in the real-world setting
Neoadjuvant Nivolumab/Ipilimumab Yields 95% Major Pathological Response Rate in dMMR Colon Cancer
September 13th 2022Neoadjuvant immunotherapy starkly outperformed neoadjuvant chemotherapy in eliciting major pathological responses among patients with mismatch repair–deficient colon cancer, according to investigators.
Adkins Discusses Benefit of Second-line CAR T-Cell Therapy in Large B-Cell Lymphoma
August 4th 2022Sherry Adkins, MSN, ANP-C, discusses the significance of incorporating CAR T-cell therapy regimens, such as lisocabtagene autoleucel, into earlier lines of treatment for patients with relapsed/refractory large B-cell lymphoma.
ESMO Guideline on Liquid Biopsy Address Quality Standards for Clinical Implementation
July 27th 2022In early-stage cancers, ctDNA has a role in screening, neoadjuvant monitoring, identification of molecular residual disease (MRD), molecular relapse monitoring, and early assessment of treatment response.
7.5-Year Follow-Up Affirms Nivolumab’s Superiority Over Ipilimumab in Advanced Melanoma
July 13th 2022Nivolumab, whether in combination with ipilimumab or as a monotherapy, was associated with improved overall survival, progression-free survival, and melanoma-specific survival, compared with ipilimumab in advanced melanoma.
5-Year Survival Data Showcases Long-Term Benefit With Nivolumab/Ipilimumab-Treated Metastatic NSCLC
June 12th 2022Frontline nivolumab and ipilimumab combination therapy was associated with increased 5-year survivorship in patients with metastatic non–small cell lung cancer—regardless of PD-L1 expression.